This is in line with previously published studies that showed FGF-21 was increased in obesity and NAFLD [37] and that decreased soluble TWEAK levels are associated with increased risk of diabetes [38,39] and metabolic syndrome [40]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.